期刊
CANCER LETTERS
卷 446, 期 -, 页码 25-37出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2018.12.021
关键词
Multi-targeting drugs; RTK inhibitors; Integrin ligands; Selective cell-internalization
类别
资金
- Ente Cassa di Risparmio di Firenze [2013.0688]
- Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR, PRIN2015) [20157WW5EH]
- Istituto Toscano Tumori [7197 29/12/2009]
Drug resistance and off-organ toxicity remain unsolved issues in chemotherapy of advanced-stage melanoma patients. Thus, the creation of new molecular conjugates able to combine a selective accumulation, high ability of internalization and signaling pathway inhibition, are highly requested. Recently, we reported a new class of molecular conjugates, compounds 1-3, where the anti-alpha(v)beta(3) integrin peptidomimetic c(AmpRGD), which is a selective ligand for alpha(v)beta(3) integrin, was covalently bound to the tyrosine kinase inhibitor sunitinib. Here, we report that these c(AmpRGD)-sunitinib conjugates and, in particular, compound 3, are selectively internalized by human melanoma cells through alpha(v)beta(3) receptor-mediated endocytosis. Compound 3 is more effective than sunitinib in reducing in vitro melanoma cells proliferation, cloning efficiency, migration, and invasion. More interestingly, compound 3 is able to significantly reduce the growth of xenografted melanoma tumor developed in immune-compromised mice, more efficiently than an equimolar dose of sunitinib. Indeed, its targeting ability was demonstrated by the selective localization at the tumor level with respect to healthy tissues. Thus, c (AmpRGD)-sunitinib conjugates such as compound 3 could serve as intriguing multiple-target agents to selectively reach melanoma cells and interfere with the progression of the disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据